Tarsus Pharmaceuticals
Tarsus Pharmaceuticals' revenue rose 146.7% to $451 million in fiscal 2025. Its operating margin was −15.7%, up from −65.9% a year earlier. Free cash flow was −$22 million. The diluted share count rose 11.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Tarsus Pharmaceuticals does
Tarsus Pharmaceuticals is a biopharmaceutical company that sells an eye medicine and develops others. Its product, XDEMVY, is an eye drop approved by the FDA in July 2023 and launched in August 2023. It treats Demodex blepharitis, an infection of the eyelids by tiny mites that causes inflammation, redness and irritation. Left untreated, it can damage the cornea.
The company says the disease may affect as many as 25 million people in the United States. It earns its revenue from selling XDEMVY. The drug's active ingredient is lotilaner, which kills the mites. The company says XDEMVY has produced $646 million in net product sales since launch.
Tarsus is also studying lotilaner in other uses. TP-04 is a gel for ocular rosacea. TP-05 is a tablet being studied to prevent Lyme disease and to reduce malaria in communities. It has also tested XDEMVY in patients who have both Demodex blepharitis and meibomian gland disease, a blockage of the oil glands in the eyelid.
Its biggest risks, as it describes them
- Depending heavily on sales of XDEMVY and on the success of its other product candidates.
- The market for XDEMVY may turn out smaller than the company estimates.
- Its product candidates may never win FDA approval or other regulatory approvals.
- Side effects from its drugs could halt trials or hurt acceptance of XDEMVY.
- Difficulty managing the growth of its sales, marketing and operations teams.
Income statement
Tarsus Pharmaceuticals lost money in fiscal 2025: a net loss of $66 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 172 | 217 | 227 | 291 | 417 |
| Debt incl. finance leases | 0 | 19 | 30 | 72 | 72 |
| Net debt (negative means net cash) | −172 | −198 | −198 | −220 | −345 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.1x | 0.1x | 0.3x | 0.2x |
| Interest coverage | — | −28.5x | −42.8x | −15.4x | −7.9x |
| Current ratio | 15.3x | 14.6x | 6.9x | 4.4x | 3.9x |
| Quick ratio | 15.3x | 14.6x | 6.8x | 4.4x | 3.8x |
Cash flow
Projections
Project Tarsus Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Tarsus Pharmaceuticals shares on the open market, and 9 insiders sold $20.0 million, $12.7 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | William J Phd LinkDirector | Sold plan | 12,500 | $78.38 | $979,744 | Form 4 |
| Sep 4, 2026 | Elizabeth Yeu LinChief Medical Officer | Sold plan | 13,953 | $87.50 | $1.2 million | Form 4 |
| Sep 4, 2026 | Bobak R. AzamianPresident/CEO and Board Chair, Director | Sold plan | 10,000 | $90.56 | $905,600 | Form 4 |
| Sep 4, 2026 | Seshadri NeervannanChief Operating Officer | Sold plan | 4,564 | $85.00 | $387,940 | Form 4 |
| Sep 2, 2026 | Bobak R. AzamianPresident/CEO and Board Chair, Director | Sold plan | 10,000 | $80.06 | $800,600 | Form 4 |
| Sep 2, 2026 | Elizabeth Yeu LinChief Medical Officer | Sold plan | 6,977 | $80.00 | $558,160 | Form 4 |
| Sep 1, 2026 | Elizabeth Yeu LinChief Medical Officer | Sold plan | 4,601 | $73.86 | $339,830 | Form 4 |
| Jun 17, 2026 | Bobak R. AzamianPresident/CEO and Board Chair, Director | Sold plan | 10,000 | $61.55 | $615,488 | Form 4 |
| Jun 16, 2026 | Jeffrey S FarrowSee Remarks | Sold | 14,396 | $60.95 | $877,436 | Form 4 |
| Jun 15, 2026 | William J Phd LinkDirector | Sold plan | 12,500 | $62.12 | $776,495 | Form 4 |
| Jun 15, 2026 | Katherine GoodrichDirector | Sold plan | 2,954 | $62.08 | $183,384 | Form 4 |
| Mar 20, 2026 | Seshadri NeervannanChief Operating Officer | Sold plan | 2,989 | $66.75 | $199,516 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 1 of 8 | 3 of 8 | 4 of 8 |
| Rule of 40 | −714.5% | 902.4% | 141.8% |
| Altman Z'' | 1.81 | 1.09 | 2.84 |
| Accruals ratio | −7.5% | −10.1% | −11.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 1 of 8 | 3 of 8 | 4 of 8 |
Compare
Put Tarsus Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Tarsus Pharmaceuticals | FY25 | 146.7% | −15.7% | −4.9% | — | — | 4 | |
| Arrowhead Pharmaceuticals | FY26 | −45.6% | −156.9% | −63.0% | — | — | 2 | Compare |
| ADMA Biologics | FY25 | 19.6% | 37.5% | 5.5% | 39.5% | −0.1x | 5 | Compare |
| Krystal Biotech | FY25 | 33.9% | 41.5% | 48.5% | 43.6% | −5.0x | 5 | Compare |
| Twist Bioscience | FY25 | 20.3% | −36.2% | −20.1% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | 0 | 57 | 26 | 17 | 183 | 451 |
| Revenue growth | — | — | — | −54.7% | −32.4% | 948.6% | 146.7% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 3 | 19 | 42 | 43 | 50 | 53 | 64 |
| Operating income | −4 | −27 | −12 | −63 | −143 | −121 | −71 |
| Net income | −5 | −27 | −14 | −62 | −136 | −116 | −66 |
| Diluted EPS (US$) | −1.98 | −4.32 | −0.67 | −2.52 | −4.62 | −3.07 | −1.59 |
| Diluted shares (millions) | 2 | 6 | 21 | 25 | 29 | 38 | 42 |
| Cash flow | |||||||
| Cash from operations | −4 | −21 | 4 | −49 | −118 | −83 | −12 |
| Capital expenditure | 0 | 0 | 1 | 0 | 2 | 2 | 10 |
| Free cash flow | −4 | −22 | 3 | −50 | −119 | −85 | −22 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 8 | 14 | 20 | 28 | 42 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 58 | 168 | 172 | 217 | 227 | 291 | 417 |
| Debt incl. finance leases | — | — | 0 | 19 | 30 | 72 | 72 |
| Total assets | 58 | 172 | 179 | 228 | 266 | 377 | 562 |
| Total liabilities | 1 | 6 | 12 | 35 | 68 | 152 | 219 |
| Shareholders' equity | −6 | 166 | 167 | 193 | 197 | 224 | 343 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | — | — | −21.3% | −242.9% | −820.5% | −65.9% | −15.7% |
| Net margin | — | — | −24.2% | −240.5% | −778.9% | −63.2% | −14.7% |
| Free cash flow margin | — | — | 5.5% | −191.9% | −682.0% | −46.2% | −4.9% |
| Rule of 40 (growth + FCF margin) | — | — | — | −246.6% | −714.5% | 902.4% | 141.8% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | −33.5% | −8.3% | −34.5% | −69.7% | −54.8% | −23.4% |
| Return on assets | — | −23.3% | −7.9% | −30.5% | −55.1% | −36.0% | −14.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — |